Back

Local Tumor Microenvironment Niches Correlate With Survival And Immunotherapy Response In Human Glioblastoma

Petitprez, F.; Webb, S.; Morrison, G.; Merotto, L.; Webb, J.; Xie, Y.; Guney, E.; Weiss, W. A.; Finotello, F.; Kitamura, T.; Pollard, S. M.; Pollard, J. W.

2026-02-23 cancer biology
10.64898/2026.02.23.707276 bioRxiv
Show abstract

BackgroundGlioblastoma (GBM) is an aggressive form of primary brain cancer. Recent efforts to characterize GBM using single-cell or spatially-resolved transcriptomics have revealed a tremendous intra-tumoral heterogeneity between malignant cells and between different tumor areas. However, most efforts have focused on malignant cells, and the spatial and cellular heterogeneity of the tumor microenvironment (TME) remains poorly understood. Moreover, it is unclear how TME compositions and organizations influence clinical outcomes for patients. ResultsIntegrating spatial transcriptomics, single-cell RNA-seq and histology on 25 tumors, cellular composition of the TME was estimated on over 46,000 55-m wide spots. Spatial associations were revealed between mesenchymal-like cancer cells and monocyte-derived macrophages. Spots were clustered into six unique classes of TME, exhibiting differential composition of malignant and immune cells, and distinct activation of biological pathways. Spatial transcriptomics-informed deconvolution of large-scale bulk RNA-seq datasets revealed that the niche composition of tumors associated significantly with patient survival and response to immunotherapy. Mesenchymal-like, monocyte-derived macrophages-rich and hypoxic niche N1 associated with lower overall survival while oligodendrogial progenitor-like and microglia-derived macrophages-enriched niche N5 is associated with longer patients survival. Analysis of data from patients treated with immunotherapy showed that niches N1 and mixed mesenchymal-like and astrocyte-like niche N3 associated with response to PD-1 inhibitors. ConclusionsOur results show that GBM exhibits a strong spatial heterogeneity of TMEs, with distinct categories of niche. The niche composition of tumors associated with survival and immunotherapy response. Our results suggest incorporation of TME niches as biomarkers for risk stratification and therapeutic decisions for patients.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Neuro-Oncology
◐ 30 papers in training set
Top 0.1%
32.8%
2
Neuro-Oncology Advances
◐ 24 papers in training set
Top 0.1%
17.4%
50% of probability mass above
3
npj Precision Oncology
○ 48 papers in training set
Top 0.1%
4.3%
4
PLOS ONE
● 4510 papers in training set
Top 40%
3.6%
5
Genome Medicine
○ 154 papers in training set
Top 2%
3.6%
6
Cancer Research
● 116 papers in training set
Top 1%
3.1%
7
Acta Neuropathologica Communications
○ 81 papers in training set
Top 0.3%
3.1%
8
Scientific Reports
○ 3102 papers in training set
Top 43%
2.9%
9
Nature Communications
○ 4913 papers in training set
Top 44%
2.6%
10
Neoplasia
○ 22 papers in training set
Top 0.2%
1.9%
11
Clinical Cancer Research
● 58 papers in training set
Top 1%
1.3%
12
Cell Reports Medicine
○ 140 papers in training set
Top 5%
1.2%
13
Cancer Letters
○ 32 papers in training set
Top 0.4%
1.2%
14
Computers in Biology and Medicine
○ 120 papers in training set
Top 4%
0.9%
15
International Journal of Cancer
○ 42 papers in training set
Top 1%
0.9%
16
JCI Insight
● 241 papers in training set
Top 6%
0.9%
17
Frontiers in Oncology
○ 95 papers in training set
Top 3%
0.9%
18
Laboratory Investigation
○ 13 papers in training set
Top 0.2%
0.8%
19
Clinical Epigenetics
○ 53 papers in training set
Top 1.0%
0.8%
20
eLife
● 5422 papers in training set
Top 58%
0.7%
21
Communications Medicine
○ 85 papers in training set
Top 1%
0.7%
22
Journal of the Neurological Sciences
○ 17 papers in training set
Top 0.8%
0.7%
23
Cancers
○ 200 papers in training set
Top 5%
0.6%